The seventh edition of the International Meeting on Pulmonary Hypertension Clinical Treatment (IMPAHCT), organized by the ...
ATXA Therapeutics, a Dublin-based pharmaceuticals business, expects to start the first trials with patients of its lung and ...
Pulmonary arterial hypertension is caused by narrowing of the blood vessels in the lungs. Learn how it happens, including ...
Early diagnosis of COPD, chronic obstructive pulmonary disease, increases the quality of life of the patient and the efficacy of available treatments.
Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the U.S. Food and Drug ...
Liquidia (LQDA) announced that the U.S. Food and Drug Administration has accepted its New Drug Application resubmission for YUTREPIA inhalation ...
Health on MSN3d
What's the Difference Between Asthma and Chronic Obstructive Pulmonary Disease (COPD)?Medically reviewed by Sanja Jelic, MD Asthma and chronic obstructive pulmonary disease (COPD) are chronic respiratory (lung) ...
Following the presentations, each poster will be available on the Publications page of Liquidia's website at https://liquidia.com/publications.
A larger diameter of the main pulmonary artery predicts poorer outcomes in pulmonary arterial hypertension (PAH) patients, a study found.
Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback